These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12703198)

  • 41. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.
    Stephens TC; Smith MN; Waterman SE; McCloskey ML; Jackman AL; Boyle FT
    Adv Exp Med Biol; 1993; 338():589-92. PubMed ID: 8304186
    [No Abstract]   [Full Text] [Related]  

  • 42. Sulfamide antifolates inhibiting thymidylate synthase: synthesis, enzyme inhibition and cytotoxicity.
    Pawełczak K; Makowski M; Kempny M; Dzik JM; Gołos B; Rode W; Rzeszotarska B
    Acta Biochim Pol; 2002; 49(2):407-20. PubMed ID: 12362982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histone deacetylase inhibitors: from bench to clinic.
    Paris M; Porcelloni M; Binaschi M; Fattori D
    J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
    [No Abstract]   [Full Text] [Related]  

  • 44. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 45. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New nucleoside analogues in clinical development.
    Faderl S; Gandhi V; Kantarjian H; Plunkett W
    Cancer Chemother Biol Response Modif; 2002; 20():37-58. PubMed ID: 12703199
    [No Abstract]   [Full Text] [Related]  

  • 47. Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family.
    Ferrari S; Losasso V; Costi MP
    ChemMedChem; 2008 Mar; 3(3):392-401. PubMed ID: 18270995
    [No Abstract]   [Full Text] [Related]  

  • 48. Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
    Sawyers CL
    Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871
    [No Abstract]   [Full Text] [Related]  

  • 49. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 50. Biological effects of folic acid antagonists with antineoplastic activity.
    Jackson RC
    Pharmacol Ther; 1984; 25(1):61-82. PubMed ID: 6387725
    [No Abstract]   [Full Text] [Related]  

  • 51. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An update on thymidylate synthase inhibitors.
    Hughes A; Calvert H
    Ann Oncol; 1999 Oct; 10(10):1137-9. PubMed ID: 10586328
    [No Abstract]   [Full Text] [Related]  

  • 53. Stopping the spread of cancer.
    Ewan S
    Drug Discov Today; 2005 Feb; 10(3):162-3. PubMed ID: 15708525
    [No Abstract]   [Full Text] [Related]  

  • 54. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
    Fukui Y; Oka T; Nagayama S; Danenberg PV; Danenberg KD; Fukushima M
    Int J Mol Med; 2008 Dec; 22(6):709-16. PubMed ID: 19020767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimetabolites.
    Grem JL; Chabner BA; Chu E; Johnson P; Yeh GC; Allegra CJ
    Cancer Chemother Biol Response Modif; 1991; 12():1-25. PubMed ID: 1834143
    [No Abstract]   [Full Text] [Related]  

  • 56. Src continues aging: current and future clinical directions.
    Kopetz S; Shah AN; Gallick GE
    Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
    Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
    Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New targets for cancer chemotherapy.
    Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA
    Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.